Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of ELA026 in treatment-naive malignancy-associated secondary hemophagocytic lymphohistiocytosis
NL-OMON60243Phase 3Recruiting
- Sponsor
- Electra Therapeutics
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of ELA026 in haemophagocytic lymphohistiocytosis (HLH) (2 cohorts), sponsored by Electra Therapeutics. Primary endpoint: 56-day survival from time of diagnosis. Started Oct 2025; status: recruiting.
02
Drugs
ELA026
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NL-OMON60243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60243.